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outcomes, RCT estimates may overestimate the effective-
ness of treatments in practice. Instrumental Variable (IV) es-
timation techniques applied to retrospective healthcare data
can yield unbiased treatment estimates for patients at the
“extensive margin” of practice. As a result, it can be shown
that IV estimates are better suited to evaluate the cost-effec-
tiveness of policies that modify existing treatment rates.
OBJECTIVE: To estimate cost-effectiveness ratios using
treatment estimates from IV techniques and contrast these
results to cost-effectiveness ratios obtained using RCT esti-
mates.
METHODS: Data from 18,795 Iowa Medicaid eligible
children with an index event of acute otitis media (AOM)
from 1989 to 1995 were collected. Instrumental variables
were constructed for each patient based on their relative
access to various provider types. IV estimates were used
to estimate cost-effectiveness ratios for AOM patients on
the extensive margin.
RESULTS: For these patients, IV estimates of the differ-
ence in cure rates between patients that were treated with
antibiotics and those not treated ranged from 11% to
13% and were statistically significant from zero at the 1%
level. These estimates are less than 15% difference in cure
rates from RCTs (Rosenfeld et al. Journal of Pediatrics.
1994). Using the average antibiotic prescription charge ob-
served from our sample, IV estimates translate into cost-
effectiveness ratios between $123 and $145 per additional
cured patient. In contrast, the RCT estimate yields a cost-
effectiveness ratio of $107 per additional cured patient.
CONCLUSION: If patients are heterogenous with re-
spect to treatment outcomes, cost-effectiveness ratios es-
timated using RCT treatment estimates will understate
the costs per outcome from changing existing treatment
rates. IV estimation with retrospective data provides a
useful alternative for policy-makers to evaluate costs per
outcome at the margins of practice.
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OBJECTIVE: Cost-effectiveness of strategies for treating
hepatitis C.
METHODS: A decision analytic Markov model was cre-
ated comparing strategies employing interferon and inter-
feron  ribavirin: 1) IFN  interferon, 12 months; 2)
IFN/CMB  interferon 12 months, followed by 6 months
of combination therapy (interferon  ribavirin) for IFN
failures; 3) IFN/CMB-R  interferon 12 months, fol-
lowed by 6 months of combination therapy for IFN re-
lapsers; 4) CMB  combination therapy, 6 months; 5)
CMB-G  genotyping, followed by 12 months of combi-
nation therapy for genotype 1, 6 months for others. In-
terferon therapy was stopped after 3 months for non-
responders. Sustained virologic response (SVR) 6 months
post-treatment was considered to be a cure. There were
seven Markov states: well, chronic hepatitis C, compen-
sated cirrhosis, decompensated cirrhosis, hepatic cellular
carcinoma, liver transplantation, dead. Only direct medi-
cal costs were considered. Model parameters were from
published literature, utility assessments of patients, Medi-
care fee schedules, and wholesale drug prices. Patients
were followed until death. Costs and health benefits were
discounted at 3%. Sensitivity analyses were performed
using 95% CIs for probabilities, doubling and halving
cost parameters, and wide ranges for utilities.
RESULTS: The genotyping (CMB-G) strategy produced
the highest SVR. Despite having the highest cost, its in-
cremental cost-effectiveness ratio (ICER) was just $7552/
QALY (quality-adjusted life-year) compared to the sec-
ond best strategy, IFN/CMB. All other strategies were
dominated. The model was only sensitive to the response
of genotype 1 to combination therapy. As the initial re-
sponse rate of genotype 1 approaches the lower limit of
the 95% CI, interferon followed by combination therapy
(IFN/CMB) became cost-effective, with the ICER of geno-
typing reaching $137,000/QALY.
CONCLUSION: Combination therapy, with duration
based on genotype, is the most cost-effective treatment of
chronic hepatitis C.
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OBJECTIVE: To compare additional antibiotic usage for
subjects randomized to Clari or Azi for the treatment of
S. pyogenes pharyngitis/tonsillitis.
METHOD: Subjects with symptoms of streptococcal
pharyngitis/tonsillitis and S. pyogenes positive were en-
rolled in a randomized, multicenter, investigator blind,
parallel comparative control study of 10 days Clari
(250mg bid) versus 5 days Azi (250mg bid on day 1 then
qd on days 2–5). Subjects were evaluated at the end of
the treatment, at 2 weeks and at 5 weeks. Clinical and
bacteriological evaluations as well as additional or con-
comitant antibiotics were evaluated at each visit.
RESULTS: A total of 525 subjects aged 12 years and older
were enrolled and randomized (Clari n  260; Azi n 
265). The bacteriological eradication and clinical cure
rates for Clari and Azi were 94% [195 of 207] versus 77%
[155 of 202] (p  0.001) and 98% [200 of 205] versus
90% [182 of 202] (p  0.002), respectively, based on per-
protocol analysis. A total of 445 subjects (Clari n  221;
Azi n  224) were evaluable for the intent-to-treat analy-
sis. There was a greater rate of additional antibiotic usage
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in the Azi group (12%, 26 of 224) compared to the Clari
group (6%, 14 of 221). The total drug costs for additional
antibiotics were $853 and $690 for the Azi and Clari
groups, respectively. The major reason for additional anti-
biotics was due to bacteriological and clinical failures.
CONCLUSIONS: Clari is superior to Azi in the eradica-
tion of S. pyogenes and in the resolution of symptoms of
pharyngitis/tonsillitis. In addition, more subjects in the
Azi group had additional antibiotics prescribed for phar-
yngitis/tonsillitis during the follow-up period. The lower
rate of additional antibiotic usage would be expected to
result in cost savings in the overall management of phar-
yngitis/tonsillitis.
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OBJECTIVE: To supplement previous efficacy analyses
from pivotal Phase III trials with a comparison of the
community-acquired pneumonia (CAP)-related costs of
inpatient treatment using either IV levofloxacin or IV
ceftriaxone as initial primary therapy.
METHODS: Patients with a primary diagnosis of CAP
were enrolled in a prospective, randomized, open-label, ac-
tive-controlled Phase III clinical trial. They were assigned
to one of two treatment groups: levofloxacin (IV or PO)
and ceftriaxone (IV) and/or cefuroxime axetil (PO) in in-
patient and outpatient settings. Resource utilization data
were collected alongside clinical trial data. To make legiti-
mate and meaningful cost comparisons between similar
types of patients (inpatients) getting similar (IV) drugs, this
economic analysis examined only the resource utilization
of inpatient trial enrollees who received IV formulations as
initial treatment. Medicare resource cost estimates were
multiplied by resource units used by patients to generate
cost estimates. Sample size had been determined based on
efficacy endpoints in the Phase III trial protocol.
RESULTS: The results showed a statistically significant
total cost difference per patient that favored levofloxacin
over ceftriaxone ($6012 versus $7422; a difference of
$1410; p  0.048). Levofloxacin was also associated
with a statistically significant reduction in mean study
medication cost per patient ($195 versus $388; a differ-
ence of $193; p  0.0001).
CONCLUSIONS: As initial primary inpatient treatment
of adults with community-acquired pneumonia, IV levof-
loxacin is less costly than IV ceftriaxone, the most pre-
scribed inpatient CAP treatment.
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OBJECTIVES: The study purpose was to determine
whether a disease management program (DSM) using
dyspepsia guidelines would improve provider compliance
with “best practices” and result in improved health and/
or economic outcomes.
METHODS: We randomized eight clinics in a capitated
managed care medical group to “usual care” versus a dys-
pepsia DSM for non-NSAID and NSAID-related dyspep-
sia. This analysis includes only patients with non-NSAID-
related dyspepsia. The program included the use of evi-
dence-based practice guidelines, “on-site” HP testing, aca-
demic detailing of physicians, and patient education.
Symptom severity, and quality of life were measured at
baseline, 3 and 6 months, and compliance with guidelines
and utilization was assessed at 6 months.
RESULTS: One hundred sixty-seven intervention and 180
control patients entered the final analysis. There were no
significant differences in baseline characteristics in the two
groups. HP testing was performed in 61% of intervention
and 11% of control patients (P  0.001). Appropriate
anti-HP therapy was given to 100% of HP-positive inter-
vention patients and 0% of HP-positive control patients
(P  0.001). Drug costs were reduced by $4.70 PMPM in
the intervention group compared to the control group (P 
0.001). Other than a reduction in costs attributable to
barium radiography in the intervention group (P  0.05),
there were no significant differences between groups in
the costs attributable to non-drug resource utilization.
Symptom severity and quality of life scores were similar
between groups at 3 and 6 months.
CONCLUSIONS: This preliminary analysis suggests that
a DSM using evidence-based guidelines and academic de-
tailing improved the process of care for patients with dys-
pepsia not taking NSAIDs. Implementation of this DSM
resulted in significant reductions in PMPM pharmacy
costs, without compromising symptom severity or health-
related quality of life.
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